Public Release: 18-May-2015
First prospective study finds women currently using MHT are twice as likely to develop lower gastrointestinal bleeding
Digestive Disease Week
Washington, DC (May 18, 2015) — Current users of menopausal hormone therapy (MHT) are more than twice as likely than non-users to develop lower gastrointestinal bleeding and ischemic colitis, especially if they use the therapy for longer durations, according to a study (abstract 783) that was released today at Digestive Disease Week® (DDW) 2015.
“We know that estrogen and progesterone, the two hormones involved in menopausal hormone therapy, induce blood clotting, but we didn’t know whether they caused gastrointestinal bleeding,” said Prashant Singh, MD, resident physician in the department of internal medicine, Massachusetts General Hospital, Boston. “There had been reported cases of GI bleeding with menopausal hormone therapy, but this study confirms our speculation that hormonal therapy increases the risk, especially in the lower GI tract.”
Ischemic colitis, which is the blockage of blood flow to the large intestine, has previously been identified as a complication of MHT. This condition can cause blood vessels to clot, leading GI mucosa to die and causing lower GI bleeding.
In the first study of its kind, researchers conducted a prospective cohort survey of 73,863 women, comparing episodes of GI bleeding among current MHT users, past users and those who never used it. In analyzing the possible link between MHT and GI bleeding, researchers adjusted for other known risk factors of GI bleeding, including body mass index, cigarette smoking, oral contraceptive use, and use of aspirin and non-steroidal anti-inflammatory drugs (NSAIDS).
Dr. Singh and his team found that current users of MHT have about a 50 percent increased risk of experiencing an episode of major GI bleeding, compared to individuals who have never been on this therapy. Additionally, current users were more than twice as likely to experience ischemic colitis and lower GI bleeding. However, there was no difference in the occurrence of upper GI bleeding between current users and those who never used MHT. Past users did not have a more significant risk of GI bleeding than those who never used MHT.
Researchers also measured the correlation between major GI bleeding episodes and the treatment duration of MHT, and found that the longer the treatment is taken, the more likely the chance of a major GI bleed. Dr. Singh also noted that for MHT users, there was a higher risk of bleeding in the lower GI tract than in the upper, because there are fewer blood vessels supplying the lower, so clotting there has much greater impact.
“It is important for patients to know that menopausal hormone therapy is an effective treatment,” said Dr. Singh. “However, both clinicians and patients should be more cautious in using this therapy in some cases, such as with patients who have a history of ischemic colitis. The decision should be based on whether the benefits of menopausal hormone therapy outweigh the risks.”
If MHT is not an option for patients due to medical history, they may have other treatment options available to them depending on what medical condition is being treated. Patients undergoing post-menopausal treatment can talk to their health-care provider about treatments like selective serotonin reuptake inhibitor (SSRI) therapy for menopausal symptoms, such as hot flashes. If individuals are on MHT for osteoporosis, there are other medication options, such as alendronate and ilbandronate.
Dr. Singh suggests that additional studies should be conducted to confirm the team’s findings and answer other questions, such as whether specific patient populations are more prone to GI bleeding from MHT or whether one type of MHT carries a higher risk of bleeding more than another.
Dr. Prashant Singh will present data from the study “Menopausal Hormone Therapy Is Associated with Increased Risk of Lower Gastrointestinal Bleeding,” abstract 783, on Monday, May 18, at 5:15 p.m., in Room 146C of Walter E. Washington Convention Center. For more information about featured studies, as well as a schedule of availability for featured researchers, please visit http://www.ddw.org/press. Dr. Singh reports that funding for this research came from The National Institute of Diabetes and Digestive and Kidney Diseases, grant number R01DK095964. Faculty disclosures can be found online at http://www.ddw.org/DDW_Disclosure_Index.pdf.
Digestive Disease Week® (DDW) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA) Institute, the American Society for Gastrointestinal Endoscopy (ASGE) and the Society for Surgery of the Alimentary Tract (SSAT), DDW takes place May 16-19, 2015, at Walter. E. Washington Convention Center, Washington, DC. The meeting showcases more than 5,000 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology. More information can be found at http://www.ddw.org.
Categories: Lethal or Unintended Side Effects